Prospects for the prevention of stroke

Journal of Hypertension

Volumn 24, Issue SUPPL. 2, 2006, Pages

  Dahlöf, Björn ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II receptor blockers; Hypertension; Renin angiotensin system; Stroke, telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; LOSARTAN; NITRENDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY METABOLISM; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; STROKE;

EID: 33646386920     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220097.04531.6f     Document Type: Review

References (56)

1. World Health Organization. WHO World health report. Geneva: World Health Organization; 2002.
2. World Health Organization. Cardiovascular disease - prevention and control WHO CVD strategy 2001-2002. Geneva: World Health Organization, 2002.
3. Costs of CVD to the Health Care System, 2003. http:// www.heartstats.org/eucosts [accessed 5 July 2005].
4. European Stroke Initiative Executive Committee, EUSI Writing Committee. European Stroke Initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 2003; 16:311-337.
5. Alberts MJ. Update on the treatment and prevention of ischaemic stroke. Curr Med Res Opin 2003; 19:438-441.
6. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
7. Prospective Studies Collaboration. Age-specific relevance pf usual blood pressure to vascular mortality: a meta-analysis of individual data from one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
8. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
9. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:776-785.
10. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
11. Marques-Vida P, Tuomilenhto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11:213-220.
12. Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 2005; 36:725-730.
13. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 1:795-797.
14. Elliott WJ. Circadian variation in the timing of stroke onset - a meta-analysis. Stroke 1998; 29:992-996.
15. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315-1322.
16. Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987; 60:801-816.
17. Redon J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoring. Blood Press Monit 2002; 7:111-116.
18. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens 2005; 18:149-151.
19. Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997; 10:705-713.
20. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
21. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
22. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.
23. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
24. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44:1175-1180.
25. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality after Stroke. Eprosartan compared with nitrendipine for Secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
26. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
27. Strandberg TE. Secondary prevention of stroke is important: but all hypertensive drugs are not treated equal? Stroke 2005; 36:1225-1226.
28. Lombardi F, Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Des 2003; 9:1703-1713.
29. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, et al. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertens 2005; 19:301-307.
30. Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 2004; 9:46-54.
31. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
32. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
33. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
34. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.
35. Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
36. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the Cardiovascular Irbesartan Project. Hypertension 2004; 44:61-66.
37. Galzerano D, Tammaro P, Cerciello A, Breglio R, Mallardo M, Lama D, et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 2004; 18:53-59.
38. Galzerano D, del Viscovo L, Tammaro P, Lama D, Galzerano A, Breglio R, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass: a multicenter, randomized longitudinal study. Am J Hypertens 2005; 18:1563-1569.
39. Anan F, Takahashi N, Ooie T, Hara M, Yoshimatsu H, Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 2004; 53:777-781.
40. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
41. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104:2039-2044.
42. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54:230-246.
43. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2225.
44. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
45. Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21:53-57.
46. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87 (Suppl 8A):3C-9C.
47. 1 receptor blockade on neurological outcome after focal brain ischemia. Hypertension 2000; 36:656.
48. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43:1343-1347.
49. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
50. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002.
51. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20:130-139.
52. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5:58-63.
53. Williams B, Gosse P, Lowe L, Harper R, PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring. J Hypertension 2006; 24:193-200.
54. Lacourcière Y, Neutel JM, Davidai G, Koval S. A multicentre, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-112.
55. Diener H-C. Secondary prevention of stroke with antiplatelet drugs. Med Klin (Munich) 2004; 99 (Suppl 1):21-25.
56. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, et al. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004; 18:367-373.